GlassScriptPhysician profile
Pranav Bhakta
NPI 1659485092
$4,400.52
in general payments reported to CMS, 2019-2025
24 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $496 · 2021: $714 · 2022: $683 · 2023: $757 · 2024: $603 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,157.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $441.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $256.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $253.88 | 2023-2025 | Repatha, Tavneos, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.19 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Pfizer INC. | $188.11 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $155.43 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $118.99 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.06 | 2022-2024 | |
| Indivior INC. | $78.12 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $49.02 | 2021 | |
| Orexo US, INC. | $47.42 | 2019-2020 | |
| Abbvie INC. | $44.92 | 2020-2025 | |
| Abbott Laboratories | $44.50 | 2022 | |
| Allergan, INC. | $41.10 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.61 | 2021-2023 | Xifaxan, Trulance |
| Angiodynamics, INC. | $30.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.72 | 2021-2022 | |
| Antares Pharma, INC. | $23.22 | 2025 | Xyosted |
| Novo Nordisk INC | $20.90 | 2025 | Ozempic |
| Kowa Pharmaceuticals America, INC. | $18.11 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.59 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $16.24 | 2023 | Quviviq |
| Eisai INC. | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranav Bhakta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.